FDA grants orphan drug status to an experimental drug for squamous NSCLC

An experimental drug called, veliparib, is being studied for treatment of patients with squamous NSCLC. This drug is a "PARP" inhibitor and may be used with chemotherapy or radiation to help improve efficacy. Although it's too early to tell if this drug will be FDA-approved, the possibility of having another treatment option is exciting news. A press release can be found here: biospace.com/News/abbvie-re...

Skip

Featured Content

Awareness about Lung Cancer diagnosis

If you’ve been diagnosed with lung cancer, please take this short survey and add your voice as an advocate today.

Complete the survey

Featured by HealthUnlocked

oldestnewest

    You may also like...